Plasminogen activators and plasminogen activator inhibitor 1 before and after venous occlusion of the upper limb in thromboangiitis obliterans (Buerger's disease)

Thrombosis Research

Volumn 66, Issue 4, 1992, Pages 321-329

  Choudhury, N A ^a   Pietraszek, M H ^a   Hachiya, T ^a   Baba, S ^a   Sakaguchi, S ^a   Takada, Y ^a   Takada, A ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Buerger's disease; Plasminogen Activator Inhibitor 1; Plasminogen activators; venous occlusion

Indexed keywords

PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR;

ADULT; ARTICLE; BUERGER DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; VEIN OCCLUSION;

ARM; CONSTRICTION; FIBRINOLYSIS; HUMAN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; THROMBOANGIITIS OBLITERANS; VEINS;

EID: 0026735775     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/0049-3848(92)90282-F     Document Type: Article

References (14)

1. Thromboangiitis obliterans and arteriosclerosis obliterans: Clinical and prognostic differences
2. Enhanced platelet response to serotonin in Buerger's disease
3. t-PA, PAI and protein C before and after vascular occlusion of the upper limb in patients with Raynaud's phenomenon
4. The incidence of protein C and S deficiency in 139 young thrombotic patients
5. Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: A study in 83 patients with confirmed deep vein thrombosis
6. Reduced fibrinolytic potential in patients with arterial occlusive disease (AOD) in comparison with normal subjects
7. A prospective survey of risk factors in young adults with arterial occlusive disease
8. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1
9. Characterization of various antibodies against tissue plasminogen activator using highly sensitive enzyme immunoassay
10. Measurement of the concentration of free plasminogen activator inhibitor (PAI-1) and its complex with tissue plasminogen activator in human plasma
11. The postoperative fibrinolytic shutdown; a rapidly reverting acute phase pattern for a fast-acting inhibitor of tissue plasminogen activator after trauma
12. Angiogenic factors
13. Characterization of a Mr 20000 basic fibroblast growth factor-like protein secreted by normal and transformed fetal bovine aortic endothelial cells
14. Malignant transformation of human fibroblasts correlates with increased activity of receptor-bound plasminogen activator